Pathelium develops regenerative therapies for chronic diseases by targeting epithelial dysfunction. The company engineers CRISPR-optimized stem cells delivered via AI-driven biomaterials to restore tissue barrier function and achieve durable disease remission.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic diseases such as Inflammatory Bowel Disease (IBD) and Chronic Obstructive Pulmonary Disease (COPD) are often managed with therapies that focus on symptom control rather than addressing the underlying cellular dysfunction. This approach can lead to persistent disease activity and a reduced quality of life for patients.
Solution
Pathelium is developing curative therapies that target the root cause of chronic diseases through epithelial regeneration. The company leverages CRISPR-optimized stem cells, which are engineered for enhanced therapeutic efficacy and engraftment. These cells are delivered using AI-driven biomaterials that facilitate controlled release and integration into damaged tissues. This regenerative approach aims to restore the integrity and function of the body's epithelial barriers, providing durable, long-term disease remission.
Target Audience
Pathelium's primary customers are patients suffering from chronic diseases like IBD and COPD, and the healthcare providers who treat them, including gastroenterologists, pulmonologists, and regenerative medicine specialists.
Features
- CRISPR-optimized autologous stem cell therapy for enhanced therapeutic potential.
- AI-driven biomaterial scaffolds for controlled cell delivery and tissue integration.
- Focus on epithelial regeneration to restore tissue barrier function.
- Pipeline targeting chronic inflammatory and degenerative diseases, including IBD and COPD.
- Proprietary cell expansion and differentiation protocols.